GLP-1 Pharmacy Fulfillment for Telehealth Brands (2026)

GLP-1 pharmacy fulfillment for a telehealth brand is a seven-stage pipeline: a licensed provider writes the prescription after reviewing intake; the e-prescription travels over Surescripts to a pharmacy licensed in the patient's state; the pharmacy routes the order to a branded product (Wegovy, Zepbound, Ozempic and related labels) or, where the prescriber has documented a patient-specific reason, to a 503A compounded preparation; the pharmacy packs the medication in a validated cold-chain shipper and hands it to a carrier on a schedule that avoids weekend dwell; the patient receives it, with lot number and beyond-use or expiration date on the label; refills follow the provider's titration schedule, not a subscription timer; and failed deliveries, temperature excursions and side-effect reports route back to the pharmacy and the provider rather than to the brand's support desk. The brand owns the customer, the storefront and the program price; it never touches the drug. Since FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, branded-versus-compounded routing is the stage that most often breaks a program, so it gets the longest treatment below, along with 0% markup economics, what OrbitRx does at each stage, and the questions to ask any fulfillment vendor.

This is general information, not legal or medical advice. Compounded drugs are not FDA-approved. Every decision about candidacy, medication, dose and refills rests with the treating licensed provider.

Key takeaways

• A GLP-1 order moves through seven stages, and the brand owns only the first (storefront and intake) and the last (patient communication); prescribing, dispensing and shipping belong to licensed providers and pharmacies.
• FDA declared the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage resolved on February 21, 2025, which ended the shortage-based basis for compounding essentially-copies; 503A compounding now requires a patient-specific, prescriber-documented significant difference.
• In April 2026 FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, and in March 2026 it sent 30 warning letters to telehealth companies over compounded GLP-1 marketing, so routing and advertising both need a conservative posture.
• Wegovy and Zepbound labeling calls for refrigerated storage at 2°C to 8°C, so fulfillment requires validated cold-chain packaging, carrier scheduling and an excursion policy, not a padded envelope.
• 0% medication markup means the pharmacy's price passes through to the brand unchanged; the brand sets the program price, and the platform's fee is flat rather than a cut of each vial.

Who this is for

• Founders launching or scaling a GLP-1 weight-loss brand who need to understand what happens after the provider approves a prescription.
• Med spa and clinic operators adding home-delivered GLP-1 programs to an in-person practice.
• Operators choosing between a platform-managed pharmacy network, a direct pharmacy contract and owning a pharmacy.

How does a GLP-1 prescription get from intake to the patient's door?

Here is the pipeline, stage by stage, with the owner of each stage. The owner is the entity that is legally responsible for the stage, not the one whose logo the patient sees.

GLP-1 medications are not controlled substances, so EPCS and DEA registration do not apply to this pipeline. They do apply if the same brand prescribes testosterone or other scheduled drugs, which is why an e-prescribing system should be EPCS-ready even for a weight-loss program that will later add men's health.

What does e-prescribing via Surescripts actually do?

Surescripts is the national e-prescribing network that connects prescribers' software to pharmacies. The prescription leaves the provider's console as a structured NCPDP SCRIPT message (drug, strength, sig, quantity, refills, prescriber identity) and lands in the pharmacy's management system without re-keying. For a GLP-1 program it does three useful things: it eliminates the fax-and-phone loop that delays first shipments, it provides a transaction record that ties a specific prescriber to a specific order, and it lets the pharmacy's system check the prescription against the patient's profile before filling.

It does not choose the pharmacy or verify its licensure in the patient's state; that is the platform's and the pharmacy's job.

How do you select a pharmacy, and why does state licensure matter?

A pharmacy shipping into a state must hold that state's resident or nonresident pharmacy license, and for sterile compounded preparations several states require additional permits. California, Texas and Florida, for example, each impose nonresident pharmacy licensing and, for sterile compounding, additional permit or pharmacist-in-charge requirements; the specifics change, so verify each on the state board's site. Practically, a national program needs a pharmacy network rather than one pharmacy, because no single pharmacy holds every license and every product.

Selection criteria for a GLP-1 pharmacy partner:

• Licensure map. Which states, which products (branded, sterile compounded, non-sterile), with license numbers.
• LegitScript certification. Google and Meta require it for the brand; the pharmacy's own certification matters too. The LegitScript page describes MyOrbitHealth's managed certification.
• Accreditation and inspection history. State board inspection reports, and for 503B facilities FDA inspection history and CGMP compliance.
• USP compliance. USP <797> governs sterile compounding (the current version became official November 1, 2023), and USP <795> governs non-sterile compounding. Injectable GLP-1 preparations are sterile and fall under <797>, including its beyond-use dating rules.
• Cold-chain validation. Documented shipper qualification, refrigerant packs, seasonal profiles, and an excursion policy.
• Capacity and turnaround. Fill-to-ship time in business days, and what happens at volume.

For the deeper framework, see compounding pharmacy partnerships and the white-label pharmacy guide.

How does routing between branded and compounded GLP-1 work after the shortage resolutions?

This is the stage to get right. The legal basis for mass compounding of GLP-1s was the FDA drug shortage list, and that basis is gone.

The timeline. FDA declared the tirzepatide shortage resolved on October 2, 2024, re-evaluated after a legal challenge and reaffirmed the decision on December 19, 2024, with enforcement discretion ending February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. FDA declared the semaglutide injection shortage resolved on February 21, 2025, with enforcement discretion ending April 22, 2025 for 503A and May 22, 2025 for 503B. A federal court sided with FDA on the tirzepatide decision in 2025, as widely reported.

The rules now. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a and 353b) prohibit compounding drugs that are essentially copies of commercially available approved products, with narrow exceptions.

• A 503A pharmacy may compound a product that differs from an approved drug only when a prescriber determines, for an identified individual patient, that the change produces a significant difference for that patient (a different strength, an added ingredient the patient needs, an allergy to an excipient). FDA's 2018 final guidance on essentially-copies under 503A states the determination must be the prescriber's and must be documented on the prescription. A justification that is pre-generated by software or pre-selected on a template is not a prescriber determination, and compliance counsel treat it as a liability rather than a defense. 503A pharmacies also may not compound regularly or in inordinate amounts.
• A 503B outsourcing facility may compound from bulk drug substances only if the substance appears on FDA's 503B bulks list or the drug is on the shortage list. On April 30, 2026, FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no demonstrated clinical need, with the notice published in the Federal Register on May 1, 2026 and a comment period that closed in summer 2026. If finalized, large-scale 503B GLP-1 compounding ends. Check the current status before you build on 503B supply.

The marketing overlay. On March 3, 2026, FDA announced 30 warning letters to telehealth companies over compounded GLP-1 marketing that implied sameness with approved drugs or presented the telehealth brand as the compounder. A brand's storefront must describe compounded products accurately, name the pharmacy as the compounder, and never promise a specific medication before a provider has decided.

What routing looks like in practice. The provider decides, patient by patient. The default route for most new patients is an approved product dispensed by a retail or mail-order pharmacy, including manufacturer direct-to-patient programs (Lilly and Novo Nordisk both operate them). A 503A compounded preparation is a documented exception for a specific patient, not a default. Our 503A vs 503B guide and compounded tirzepatide vs Zepbound explainer go further on when each route is available.

What does cold-chain packaging for GLP-1 shipping involve?

The Wegovy and Zepbound prescribing information both call for refrigerated storage at 2°C to 8°C (36°F to 46°F), with limited room-temperature allowances described in the labels. Compounded sterile preparations carry beyond-use dates and storage conditions set under USP <797>. The pharmacy's job is to deliver the product within its labeled conditions and to be able to prove it.

• Shipper qualification. An insulated container plus refrigerant (gel packs or phase-change material) that has been tested against summer and winter profiles for the transit time the pharmacy actually uses. USP <1079> (Good Storage and Shipping Practices) is the reference standard.
• Pre-conditioning. Refrigerant conditioned to the right temperature before packing; frozen gel packs against a vial can freeze the product, which is as damaging as heat.
• Carrier rules. Overnight or two-day service with tracking; ship Monday through Wednesday so packages do not sit in a warehouse over a weekend; signature or photo-on-delivery where the state or pharmacy requires it; address verification before release. Carriers have their own hazardous-material and dry-ice rules; most GLP-1 shipments use gel packs and avoid them.
• Temperature indicators. Single-use indicators or data loggers in the shipper let the pharmacy and patient confirm the product stayed in range.
• Excursion policy. Written rules for what happens when a package is late, left in the sun, or arrives warm: who evaluates, whether the product is replaced, and who pays. The pharmacy makes the product-integrity call; the brand communicates.
• Patient instructions. Refrigerate on arrival; what a "do not use" condition looks like; how to report a problem.

How are lots tracked, and what records does the pharmacy keep?

For approved products, the Drug Supply Chain Security Act requires trading partners to exchange and keep transaction information; dispensers have been phasing into its enhanced requirements through 2024 and 2025, with FDA granting exemptions for smaller dispensers into 2026. For compounded preparations, DSCSA does not apply, but state board rules and USP <797> require compounding records that identify each batch, its components and lot numbers, the beyond-use date and the compounder. The label on every shipped product should show the drug, strength, quantity, lot or batch, expiration or beyond-use date, storage instructions and the dispensing pharmacy's name and address.

For the brand, lot tracking matters in a recall (the pharmacy must identify every patient who received the lot) and in an adverse event (the provider and pharmacy need the lot to report through FDA MedWatch). The platform's job is to expose dispense events so the support team can answer "did it ship?" without touching clinical data.

How do refills and titration work?

GLP-1 therapy escalates in steps. The Wegovy label describes a dose escalation over about 16 weeks to the maintenance dose, and the Zepbound label describes 2.5 mg for four weeks followed by increases in 2.5 mg increments at intervals of at least four weeks; a provider may slow, hold or reverse that schedule based on tolerability. The consequence for fulfillment is that a GLP-1 refill is not a subscription renewal. Each refill is a clinical decision that sets the next strength, and the pharmacy fills that strength.

An operational refill loop looks like this:

1. The platform prompts the patient for a check-in before the next fill is due (weight, side effects, missed doses).
2. The provider reviews the check-in, documents it, and prescribes the next dose or holds.
3. The pharmacy receives the new prescription or the authorized refill and ships on its cold-chain schedule, timed so the patient has medication before the current supply ends.
4. Billing on the storefront matches the clinical cadence (four-week supplies are common), with the brand as merchant of record.

Brands that let the subscription engine drive the pharmacy, rather than the provider, create both a clinical problem and a regulatory one.

What happens when a delivery fails?

Plan for four failure modes before launch.

• Carrier delay or misroute. Tracking shows the package stalled. The pharmacy evaluates whether the shipper's qualified duration has elapsed; if so, it re-ships. The brand tells the patient what is happening and when the replacement arrives.
• Delivered but not received (wrong address, porch theft). The brand's support team handles the logistics conversation; the pharmacy's policy determines whether a replacement is sent and at what cost; the provider may need to issue a new prescription.
• Temperature excursion. The patient reports a warm package or a tripped indicator. The pharmacy makes the integrity determination, not the brand, and documents it.
• Patient unreachable or address change mid-titration. Hold the shipment; a provider review may be needed if the gap is long enough to restart the escalation.

Every one of these should have a named owner and a patient-facing script. The HIPAA-compliant patient messaging guide covers where the brand's support team must stop and where the provider takes over, including side-effect reports that arrive disguised as shipping complaints.

How do 0% markup economics work?

Two pricing models exist for GLP-1 fulfillment. In the markup model, the platform or pharmacy intermediary adds a margin to the medication cost, so the brand's cost per vial rises with volume and the intermediary's incentive is to maximize dispensing. In the pass-through model, the pharmacy's price reaches the brand unchanged, the platform charges a flat fee for the infrastructure, and the brand sets the program price to the patient.

MyOrbitHealth uses the pass-through model: 0% medication markup, no revenue share, a flat platform fee scoped at onboarding, and the brand as merchant of record. That has three practical effects. Gross margin on the program belongs to the brand. Price changes at the pharmacy are visible rather than buried. And the platform has no financial interest in whether a provider prescribes, which is also the cleaner posture under the corporate-practice rules discussed in our telehealth MSO companies post. As of October 2026, per their site, Cuvo Health also publishes 0% medication markup; the MyOrbitHealth vs Cuvo comparison lays out the rest of each model. Other vendors publish a merchant fee on sales or no medication pricing at all; read the white-label telehealth platform cost guide before comparing.

What does OrbitRx do in this pipeline?

OrbitRx is MyOrbitHealth's e-prescribing and fulfillment layer. From published facts:

• E-prescribing routed via Surescripts, EPCS-ready with two-factor identity proofing for programs that later add controlled substances.
• Pharmacy network that is LegitScript-certified, spanning 503A compounding and retail pharmacies, with DEA-registered partner pharmacies where applicable.
• Cold-chain shipping to all 50 states.
• 0% medication markup, with pharmacy cost passing through to the brand.
• Status events through the platform's signed webhooks, including prescription.dispensed, so a brand's storefront or support tooling can show order progress without accessing the clinical record.
• Operational visibility in OrbitOS: prescriptions, encounters, providers, queue health and reporting, with a full HIPAA audit trail.

Around it, Orbit Intake handles stage one (adaptive intake with severity scoring and red-flag escalation), the provider network handles stage two (2,400+ board-certified providers, 38+ specialties, all 50 states, average response under six minutes during business hours), and Orbit Labs supplies baseline and monitoring labs when a provider orders them. The whole stack is described on the GLP-1 weight loss solutions page.

Each step, who does it

What should you ask a GLP-1 fulfillment vendor?

1. Which pharmacies will fill for my program, and in which states is each licensed for sterile compounded and for branded products?
2. How does routing between branded and compounded supply work, and how is the prescriber's significant-difference determination documented?
3. What is your position on 503B supply given FDA's April 2026 proposal to exclude the GLP-1s from the bulks list?
4. Show me the shipper qualification data and the excursion policy. Who pays for a replacement?
5. Which days do you ship, which carriers, and what is fill-to-ship time in business days?
6. What is on the label, and how do you handle a recall by lot?
7. Is medication priced at pass-through (0% markup) or with a margin? Is there a revenue share or a merchant fee?
8. Who is merchant of record, and who owns the patient and order data?
9. How does the refill cycle tie to the provider's titration decision rather than to the subscription?
10. What events can my systems subscribe to, and how are they authenticated?
11. Can I bring my own pharmacy, and how would it be onboarded?
12. What marketing language do you require or prohibit on my storefront for compounded products?

Fold these into the broader telehealth vendor due diligence checklist when you evaluate the whole platform, and see how to launch a GLP-1 weight loss brand for everything that sits before stage one.

Frequently asked questions

Which pharmacy fills compounded GLP-1 prescriptions for telehealth brands?

A 503A compounding pharmacy licensed in the patient's state, and only when the prescriber has documented a patient-specific reason the compounded preparation produces a significant difference from the approved product. Since the FDA shortage resolutions in 2024 and 2025, compounding cannot be the default route, and FDA has proposed removing the GLP-1s from the 503B bulks list.

How do telehealth companies ship semaglutide and tirzepatide?

Through a licensed pharmacy that packs the medication in a qualified insulated shipper with conditioned refrigerant, ships overnight or two-day with tracking on weekdays, and documents the cold chain. Wegovy and Zepbound labeling calls for storage at 2°C to 8°C, and compounded sterile preparations carry beyond-use dates set under USP 797.

Is compounded tirzepatide still legal in 2026?

Only in narrow circumstances. FDA declared the tirzepatide shortage resolved in October 2024, so a 503A pharmacy may compound it only for an identified patient when the prescriber documents a significant difference, and not regularly or in inordinate amounts. 503B compounding depends on the bulks list, from which FDA proposed excluding tirzepatide in April 2026; check the current status with counsel.

Do I need my own pharmacy to start a GLP-1 telehealth business?

No. Most brands use a platform-managed network of licensed pharmacies that already hold the state licenses, LegitScript certification and cold-chain capability. Owning a pharmacy adds licensing in every state you ship to, inspections, a pharmacist-in-charge and inventory risk, which rarely makes sense before significant volume.

Do telehealth platforms mark up GLP-1 medication?

Some do, through a margin on medication cost, a revenue share or a merchant fee on sales. MyOrbitHealth passes pharmacy cost through at 0% markup with no revenue share and a flat platform fee, and the brand is merchant of record; as of October 2026, per their site, Cuvo Health also publishes 0% medication markup.

How do GLP-1 refills work with dose titration?

Each refill follows a provider decision on the next dose, usually after a patient check-in on weight, side effects and missed doses. Labeled escalation schedules move in steps of roughly four weeks, and the provider can slow or hold them. The pharmacy fills the strength the provider prescribes, and the storefront's billing cadence should match the clinical schedule rather than drive it.

What happens if a GLP-1 shipment arrives warm or is lost?

The pharmacy, not the brand, decides whether the product is still usable based on the shipper's qualified duration and any temperature indicator, and applies its re-ship policy. The brand's support team handles the patient conversation about timing, and the provider issues a new prescription if one is needed.

Can a telehealth brand use its own pharmacy with a white-label platform?

Often yes, depending on the platform; ask how a bring-your-own pharmacy is onboarded, credentialed and connected to e-prescribing. Confirm that the pharmacy holds the licenses for every state you serve and that pricing, markup and data-ownership terms stay the same.

Sources

• FDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
• FDA, Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A (final guidance)
• 21 U.S.C. 353a, Section 503A (Cornell LII)
• 21 U.S.C. 353b, Section 503B (Cornell LII)
• Federal Register, May 1, 2026: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B
• USP General Chapter 797, Pharmaceutical Compounding: Sterile Preparations
• USP General Chapter 795, Pharmaceutical Compounding: Nonsterile Preparations
• FDA, Drug Supply Chain Security Act (DSCSA)

Run GLP-1 fulfillment without touching the drug

OrbitRx connects your brand's storefront to licensed providers, Surescripts e-prescribing and a LegitScript-certified pharmacy network that ships cold-chain to all 50 states at 0% medication markup. You set the program price and own the patient; providers and pharmacies own the medicine. Book a demo or start with the GLP-1 weight loss solution overview.